FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019372207> ?p ?o ?g. }

• W2019372207 abstract "Objective: To assess the safety and feasibility of combining IV rt-PA with IV abciximab within a 24 hour period for treatment of worsening lacunar syndromes. Background Lacunar strokes are often preceded by warning syndromes and are a major cause of progressive motor deficit. Some controversy exists about the correct management of Fluctuating Lacunar Syndromes (FLS). We present our experience using IV abciximab within 24 hours of IV rt-PA thrombolysis for FLS. Design/Methods: We retrospectively identified all patients who received IV rt-PA followed by IV abciximab within a 24hr period. We excluded all patients who received IA rt-PA, mechanical thromboembolectomy, and a longer time period between rt-PA and abciximab. We identified the NIHSS score at four different times: at presentation, after IV rt-PA, before IV abciximab, and at discharge; we also reviewed imaging reports for any evidence of hemorrhagic conversion. Results: 18 patients received IV rt-PA followed by IV abciximab within 24 hours. All four NIHSS scores were recorded in 12 patients; the remaining 6 patients only had documentation of deterioration after IV rt-PA, without specific score mentioned. The overall mean admission score was 9, and the mean improvement post-TPA was a decrease of 4 (in the 12 patients). For those 12 patients, the mean deterioration post-TPA was an increase of 4, indicating a return to pre-thrombolytic stroke severity. After IV abciximab, the mean score at discharge (for all patients) was 3, for an overall improvement of 6, from admission to discharge. No hemorrhagic conversions were identified, either after IV rt-PA or after IV abciximab. Conclusions: No therapeutic options currently exist for lacunar stroke patients who deteriorate after thrombolysis with IV rt-PA. Our results suggest that abciximab may be beneficial and safe for this population. Larger randomized trials will need to be conducted to prove safety and efficacy. Disclosure: Dr. Nair has nothing to disclose. Dr. McNeil has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Jahnel has received personal compensation for activities with Genetech as a Consultant. Dr. Stapel has nothing to disclose. Dr. Stapel has nothing to disclose. Dr. Stapel has nothing to disclose. Dr. Stapel has nothing to disclose. Dr. Hodges has nothing to disclose. Dr. Beck has nothing to disclose. Dr. Alanis has nothing to disclose. Dr. Talkad has received personal compensation for activities with Genentech, Inc. as a speaker. Dr. Wang has received personal compensation for activities with Sanofi-Aventis Pharmaceuticals, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc." @default.
• W2019372207 created "2016-06-24" @default.
• W2019372207 creator A5003795480 @default.
• W2019372207 creator A5010675607 @default.
• W2019372207 creator A5010845091 @default.
• W2019372207 creator A5011777037 @default.
• W2019372207 creator A5026274834 @default.
• W2019372207 creator A5032699273 @default.
• W2019372207 creator A5037572518 @default.
• W2019372207 creator A5038833168 @default.
• W2019372207 creator A5039827205 @default.
• W2019372207 creator A5041357689 @default.
• W2019372207 creator A5053859861 @default.
• W2019372207 creator A5081180193 @default.
• W2019372207 creator A5090380767 @default.
• W2019372207 date "2012-04-22" @default.
• W2019372207 modified "2023-09-24" @default.
• W2019372207 title "Abciximab after IV rt-PA for Fluctuating Lacunar Syndrome (P07.005)" @default.
• W2019372207 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p07.005" @default.
• W2019372207 hasPublicationYear "2012" @default.
• W2019372207 type Work @default.
• W2019372207 sameAs 2019372207 @default.
• W2019372207 citedByCount "0" @default.
• W2019372207 crossrefType "journal-article" @default.
• W2019372207 hasAuthorship W2019372207A5003795480 @default.
• W2019372207 hasAuthorship W2019372207A5010675607 @default.
• W2019372207 hasAuthorship W2019372207A5010845091 @default.
• W2019372207 hasAuthorship W2019372207A5011777037 @default.
• W2019372207 hasAuthorship W2019372207A5026274834 @default.
• W2019372207 hasAuthorship W2019372207A5032699273 @default.
• W2019372207 hasAuthorship W2019372207A5037572518 @default.
• W2019372207 hasAuthorship W2019372207A5038833168 @default.
• W2019372207 hasAuthorship W2019372207A5039827205 @default.
• W2019372207 hasAuthorship W2019372207A5041357689 @default.
• W2019372207 hasAuthorship W2019372207A5053859861 @default.
• W2019372207 hasAuthorship W2019372207A5081180193 @default.
• W2019372207 hasAuthorship W2019372207A5090380767 @default.
• W2019372207 hasConcept C126322002 @default.
• W2019372207 hasConcept C141071460 @default.
• W2019372207 hasConcept C164705383 @default.
• W2019372207 hasConcept C2777798775 @default.
• W2019372207 hasConcept C2777871224 @default.
• W2019372207 hasConcept C2779581417 @default.
• W2019372207 hasConcept C3020298707 @default.
• W2019372207 hasConcept C42219234 @default.
• W2019372207 hasConcept C45393284 @default.
• W2019372207 hasConcept C500558357 @default.
• W2019372207 hasConcept C71924100 @default.
• W2019372207 hasConceptScore W2019372207C126322002 @default.
• W2019372207 hasConceptScore W2019372207C141071460 @default.
• W2019372207 hasConceptScore W2019372207C164705383 @default.
• W2019372207 hasConceptScore W2019372207C2777798775 @default.
• W2019372207 hasConceptScore W2019372207C2777871224 @default.
• W2019372207 hasConceptScore W2019372207C2779581417 @default.
• W2019372207 hasConceptScore W2019372207C3020298707 @default.
• W2019372207 hasConceptScore W2019372207C42219234 @default.
• W2019372207 hasConceptScore W2019372207C45393284 @default.
• W2019372207 hasConceptScore W2019372207C500558357 @default.
• W2019372207 hasConceptScore W2019372207C71924100 @default.
• W2019372207 hasLocation W20193722071 @default.
• W2019372207 hasOpenAccess W2019372207 @default.
• W2019372207 hasPrimaryLocation W20193722071 @default.
• W2019372207 hasRelatedWork W1514544701 @default.
• W2019372207 hasRelatedWork W1593681147 @default.
• W2019372207 hasRelatedWork W1690801972 @default.
• W2019372207 hasRelatedWork W2256883385 @default.
• W2019372207 hasRelatedWork W2283521927 @default.
• W2019372207 hasRelatedWork W2331993305 @default.
• W2019372207 hasRelatedWork W2550839566 @default.
• W2019372207 hasRelatedWork W2559943162 @default.
• W2019372207 hasRelatedWork W2561338475 @default.
• W2019372207 hasRelatedWork W2577728705 @default.
• W2019372207 hasRelatedWork W2594777140 @default.
• W2019372207 hasRelatedWork W2603188550 @default.
• W2019372207 hasRelatedWork W2777048077 @default.
• W2019372207 hasRelatedWork W2791550902 @default.
• W2019372207 hasRelatedWork W2902371834 @default.
• W2019372207 hasRelatedWork W2910831745 @default.
• W2019372207 hasRelatedWork W3158047091 @default.
• W2019372207 hasRelatedWork W3197858390 @default.
• W2019372207 hasRelatedWork W3201899129 @default.
• W2019372207 hasRelatedWork W3205475690 @default.
• W2019372207 isParatext "false" @default.
• W2019372207 isRetracted "false" @default.
• W2019372207 magId "2019372207" @default.
• W2019372207 workType "article" @default.